Table 1.
Baseline characteristics of 94 patients with initially unresectable HCC.
| Variable | Early tumor responders (n=68) | Non-early responders (n=26) | P value |
|---|---|---|---|
| Age (year) | 0.344 | ||
| >60 | 9 (13.2%) | 6 (23.1%) | |
| ≤60 | 59 (86.8%) | 20 (76.9) | |
| Gender | 1.000 | ||
| Male | 64 (94.1%) | 25 (96.2%) | |
| Female | 4 (5.9%) | 1 (3.8%) | |
| BCLC stage | 0.254 | ||
| A | 12 (17.7%) | 3 (11.5%) | |
| B | 16 (23.5%) | 3 (11.5%) | |
| C | 40 (58.8%) | 20 (77.0%) | |
| Target tumor size (cm) | 0.212 | ||
| >10 | 45 (66.2%) | 21 (80.8%) | |
| ≤ 10 | 23 (33.8%) | 5 (19.2%) | |
| Tumor number | 0.362 | ||
| 1 | 29 (42.6%) | 14 (53.8%) | |
| ≥2 | 39 (57.4%) | 12 (46.2%) | |
| Large vascular invasion | 0.192 | ||
| Yes | 37 (54.4%) | 18 (69.2%) | |
| No | 31 (45.6%) | 8 (30.8%) | |
| PVTT | 0.679 | ||
| Yes | 36 (52.9%) | 15 (57.7%) | |
| No | 32 (47.1%) | 11 (42.3%) | |
| Extrahepatic metastases | 0.066 | ||
| Yes | 5 (7.4%) | 6 (23.1%) | |
| No | 63 (92.6%) | 20 (76.9%) | |
| AFP (ng/mL) | 0.810 | ||
| >400 | 40 (58.8%) | 16 (61.5%) | |
| ≤ 400 | 28 (41.2%) | 10 (38.5%) | |
| Etiology | 0.456 | ||
| Hepatitis B | 62 (91.2%) | 22 (84.6%) | |
| Non−Hepatitis B | 6 (8.8%) | 4 (15.4%) | |
| ECOG PS | 0.030 | ||
| 0 | 43 (63.2%) | 10 (38.5%) | |
| 1 | 25 (36.8%) | 16 (61.5%) | |
| Cirrhosis | 0.669 | ||
| Yes | 55 (80.9%) | 20 (76.9%) | |
| No | 13 (19.1%) | 6 (23.1%) | |
| Ascites | 1.000 | ||
| Yes | 10 (14.7%) | 3 (11.5%) | |
| No | 58 (85.3%) | 23 (88.5%) | |
| Child-Pugh grade | 0.704 | ||
| A | 62 (91.2%) | 23 (88.5%) | |
| B | 6 (8.8%) | 3 (11.5%) | |
| ALBI grade | 0.739 | ||
| 1 | 7 (10.3%) | 4 (15.4%) | |
| 2 | 59 (86.8%) | 22 (84.6%) | |
| 3 | 2 (2.9%) | 0 (0.0%) | |
| TBIL (umol/L) | 17.5 (11.6-22.4) | 15.2 (12.9-18.6) | 0.348 |
| ALB (g/L) | 37.3 ± 4.3 | 36.3 ± 4.7 | 0.310 |
| PT (sec) | 12.9 ± 1.6 | 12.7 ±1.1 | 0.703 |
| ALT (U/L) | 42.5 (31.0-58.5) | 49.0 (35.2-75.5) | 0.199 |
| AST (U/L) | 57.0 (43.5-89.0) | 75.5 (61.8-97.8) | 0.020 |
| PLT (×109/L) | 207.5 (164.2-257.5) | 216.0 (151.8-288.5) | 0.577 |
| NLR | 1.000 | ||
| >2.82 | 34 (50%) | 13 (50%) | |
| ≤2.82 | 34 (50%) | 13 (50%) | |
| PLR | 0.356 | ||
| >146 | 32 (47.1%) | 15 (57.7%) | |
| ≤146 | 36 (52.9%) | 11 (42.3%) | |
| SIRI | 1.000 | ||
| >1.38 | 34 (50%) | 13 (50%) | |
| ≤1.38 | 34 (50%) | 13 (50%) | |
| successful conversion surgery | 0.001 | ||
| Yes | 30 (44.1%) | 2 (7.7%) | |
| No | 38 (55.9%) | 24 (92.3%) |
ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer; ALBI, albumin–bilirubin; HCC, hepatocellular carcinoma; AFP, α-fetoprotein; ECOG PS, Eastern Cooperative Oncology Group performance status; TBIL, Total bilirubin; PT, Prothrombin time; ALB, albumin; PLR, platelet to lymphocyte ratio; SIRI, systemic inflammation response index (neutrophil* monocyte to lymphocyte ratio); NLR, neutrophil to lymphocyte ratio; ALB, albumin; AST, aspartate aminotransferase; PVTT, portal vein tumor thrombosis.